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Summary of Experiments (With Definitions) 
 
  
 The blood cascading system is crucial in the maintenance of homeostasis.  This is 
pertinent within the field of biochemistry since the blood cascading system is directly affected by 
the activities of certain enzymes and proteins found in plasma that can affect blood clotting 
(Rand, 707).  Changes in such proteins and enzymes and their binding abilities can be observed 
using electrophoresis.   
All of my experiments use Heparin, a common anticoagulant that is used in hospitals.  
Protamine Sulfate performs oppositely of Heparin, inhibiting interactions between Human 
Factors and Anti-Throbin III, preventing the formation of complexes.  These experiments tested 
two polyamines, Spermine and Spermidine, to determine if they act more like Heparin and 
promote complex formation or like Protamine Sulfate and inhibit such interactions.   
Specifically, I tested Human Factors XIa, Xa, XIa, and IIa and observed their interactions with 
Anti-Thrombin III in comparison to Heparin and Protamine Sulfate. 
 
Some basic definitions* to remember while observing the data include: 
- 
Heparin:    A compound that is found in the liver and different tissues in the body that promotes 
blood coagulation 
 
Protamine Sulfate:   Reverses the anticoagulant effect of Heparin that comes from fish sperm. 
 
Eletrophoresis: a method used in clinical and laboratory research to separate molecules based on 
size and polarity.  The movement of the molecules happens through gels.   
 
Polyamines: involved in many genetic processes such as cell migration and proliferation.  
 
Spermine and Spermidine: Polyamines that that bind to the back of phosophate backbones on 
nucleic acids.   
 
*All definitions are cited in the references section. 
 
 
Materials and Methods 
 
 
 Acarylamide, A-8887, Lot # 29H0142,  N’N’-methylene-bis-acrylamide, M-7279, 
Lot # 1122H0107, Trizma Base, T-6066, Lot #1109H401, Sodium Lauryl Sulfate, L-3771, Lot 
#59H03281, Coomassie Brilliant Blue, B-0149, Lot #: 108H5080, TEMED, Lot # 59H1138, 
Heparin, H-3393, Lot # 69H1151, all come from Sigma Chemical Company (St. Louis, MO).  
Reagent Grade Methonal, Lot # 4228246 came from E.M. Science.  Isobutyl Alcohol, CAR # 
220-4 came from Baxter Healthcare (Deerfield, IL).  Enzyme Grade Glycerol, G-33, Lot # 
701544 from Fisher Scientific (Pittsburg, PA).  Mini-PROTEAN 3 system short glass plates, 
CAT # 1653308, 10 Lane Well Comb, CAT # 1653354, Spacer Glass Plates, CAT # 1653310, 
Human Factor Xa, CAT # HCXA-0060, Lot # BB0927-0.1 MG, 9.2mg/mL, Human Anti-
Thrombin III, CAT #: HCATIII-0120, Lot#: BB0419-1 MG, 7.2 mg/mL, Human Factor XIa, Lot 
# BB0326, 3.6 mg/mL,, Human Factor IXa Lot # BB0412, 7.1mg/mL, , Human Factor IIa, Lot#: 
AA1014, 9.0mg/mL, all from Haematologic Technologies, Incorporated (Essex Junction, VT).   
 The molecular weights of enzymes used are as follows: Xa- 46000 MW, ATIII- 
58000 MW, XIa- 160000 MW, IIa- 36700 MW, IXa- 45000 MW.  All human factors were 
prepared for testing in similar ways.  The major differences were in the gel preparation.  Human 
Factors Xa and IIa used 10% acrylamide gels while Human Factors XIa and IXa used 7.5% 
acrylamide gels.  Tris/NaCl buffer was added to the Human Factors for dilution.  The dilutions 
were as follows:  1.59µL IXa in 13.4µL of Tris,  4.3µL of XIa in 14.6µL of Tris,  1.95µL Xa in 
27 µL Tris,  3.60µL IIa in 18.4µL of Tris.  The glass plates were cleaned with methanol and 
filled with the resolving gel.  Resolving gels were made as follows: 7.5% Acrylamide gels: 4mL 
dH2O, 2.5mL of 1.5M Tris/HCl pH 8.8, 2.5mL acrylamide solution, and 100µL of 10% SDS, 
50µL APS, and 10µL TEMED.  The 10% resolving gel:  4.1mL dH2O, 3.2mL acrylamide stock 
solution, 2.5mL Tris pH8.8, 0.1mL 10% SDS, 50µL 10% APS, 5µL TEMED. These gels were 
pipeted into the plates and polymerized for between 30 minutes and 60 minutes.  Stacking gels 
were added on top of the resolving gels and lane combs were inserted into the stacking gel.  The 
stacking gels were made as follow: 7.5% acrylamide gel: 3mL dH2O, 1.27mL 0.5M Tris/HCl pH 
6.8, 0.65mL acrylamide stock solution, 100µL 10% SDS, 25µL 10% APS, 5µL TEMED.  The 
10% stacking gel: 5.9 dH2O, 1.5mL acrylamide stock solution,  2.5mL Tris pH 8.8, 0.1mL 10% 
SDS, 50µL 10% APS, 10µL TEMED. The stacking gels polymerized for between 30 and 45 
minutes.   The comb was removed and the gels and glass plates were put in the mini tank and 
10X running buffer was added to the inner and outer chambers.  Then, 5µL of each protein 
sample were added to their respective lane contents.  The electrophoresis machine was turned on 
and ran for approximately 60 minutes for each experiment.    The lane contents all included 2µL 
of ATIII and of each respective Human factor.  One lane had 3µL of Heparin while another had 
3µL of Protamine Sulfate.    All lane contents incubated at room temperature for 30 minutes.   
Following incubation, 5X running buffer was added to stop further reaction and dilute.  Then, 
the contents were boiled at 100 degrees Celsius for 2 minutes.   This further ensured that all 
reactions had ceased.   These mixtures were loaded into the gels.  Each lane content is detailed 


















Reagents Prepared for SDS-PAGE experiment: 
(Adapted from Coggin, 2003) 
 
1) Acrylamide Stock Solution 
a. 29.2g  acrylamide 
b. 0.8gN’N’-methylene-bis-acrylamide 
c. Take up in 100mL volumetric flask 
d. Filer via Vacuum filtration with Whatman #1 filter paper 
e. Store in a brown bottle or in the dark 
2) 1.5M Tris/HCL pH8.8: 
a. Add 36.33g Trizma base and fill to 150mL with dH2O 
b. Add 0.1M HCl droppwise to pH 8.8 
c. Bring to a total volume of 200mL 
d. Store at four degrees Celcius 
3) 0.5M Tris/HCL pH 6.8: 
a. Add 6.055g Trizma base to 50mL dH2O 
b. Ass 0.1M HCl to pH 6.8 then dilute to 100mL 
c. Store at four degrees Celcius 
4) 10% SDS Solution (w/v): 
a. Take 10g Sodium Layryl Sulfate up in 75mL dH2O 
b. Dilute to 100mL in volumetric Flask 
5) 10% APS (Ammonium Persulfate): 
a. Add 0.1g ammonium persulfate and fill to 1mL with dH2O 
b. Store at -20 degrees Celcius in 200 µL aliquots 
c. Prepare monthly for fresh solution 
6) 10X Running Buffer: 
a. Add 30.3g Trizma Base 
b. Add 144g Glycine 
c. Add 10g SDS 
d. Bring to 1000mL with dH2O, mix well but do not adjust the pH 
e. Store at four degrees Celcius 
f. If a precipitate forms, bring to room temperature before diluting with dH2O 
before use. 
7) dH2O Saturated Isobutyl Alcohol 
a. Extract isobutyl alcohol from large seperatory funnel after washing three times 
with dH2O 
b. This solution must be stored out of light 
8) Gel Equilibrium Solution A (30% Methanol, 3% Glycerol): 
a. Add 150mL methanol to 15mL glycerol 
b. Fill to 500mL with dH2O in a 500mL volumetric flask 
 
9) Gel Equilibrium Solution B (3% glycerol) 
a. Add 15mL glycerol 
b. Fill to 500mL with dH2O in a 500mL volumetric flask 
10)  5X Sample Buffer 
a. Add 21.5mL glycerol 
b. Add 15mL of 0.5M Tris/HCL stock solution pH 6.8 
c. Add 10mL 10% SDS solution 
d. Add 3.5mL of 1% Bromophenol Blue (prepared in MeOH~ 1g BPB in 100mL 
MeOH) 
e. Total volume= 50mL 
f. This solution is added to protein sample to a final concentration of 1X 
11) Coomassie Stain 
a. Add 0.5g Coomassie Brillian Blue to 250mL of ACS reagent grade methanol and 
mix well 
b. Add 200mL dH2O 
c. Add 50mL glacial acetic acid 
d. Filter via vacuum filtration using Whatman #1 filter paper 
12) Destain: 
a. Add 800mL dH20 
b. Add 100mL ACS reagent grade methanol 
c. Add 100mL glacial acetic acid in a 1000mL volumetric flask 
13) Tris/NaCl Buffer pH 8.0: 
a. Add 0.224g Trizma base 
b. Add 0.325g reagent grade NaCl 
c. Fill to 100mL with dH2O 
d. Mix well and do not adjust pH 




Individual substances used and in what quantities: 
-Anti-Thrombin III (4.10µg in 2µL; per lane) 
-Human Factor IIa, Xa, XIa , and XIa (Depends on the human factor; included in the individual 
reports of the project) 
-Protamine Sulfate (1.0µg in 3µL; per lane) 
-Heparin (1.0µg in 3µL; per lane) 
 
 











Significance and Hypothesis 
 
 While Heparin is a very commonly used compound, it may be beneficial in the future to 
find an alternative seeing how humans are becoming resistant to more and more types of drugs 
and antibiotics. By finding alternatives, we can also determine and guess how other compounds 
and proteins might behave within the blood cascading system.  If it can be accurately determined 
that one a compounds acts more like another, then perhaps it would reacts to treatments the 
same, bind to similar compounds, or even act competitively.    
 My hypothesis is that Spermine and Spermidine will act more like Protamine Sulfate and  
inhibit the formation of the human factor-ATIII complex.   I think that there may be slight 
formation of complex due to natural polarity, but as stated, I believe this complex will be 



























 The order my experiments are being presented in is the order in which I performed 
the experiments.  All experiments include figures, which were calculated using IMAGEJ, a 
program designed to analyze gel electrophoresis bands by percent.  You will also P-Values, 
which are calculations designed to determine the accuracy of the results presented.   
 First, will be Human Factor IXa with Anti-Thrombin III, followed by Human Factor 
Xa with Anti-Thrombin III, then Human Factor XIa wil Anti-Thrombin III, finishing with 

























Effects of Heparin, Protamine Sulfate, Spermine, Spermidine on the 














1. 5µL Molecular Weight Markers+ 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
2. 2.0µL (1.62µg) FIXa + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
3. 2.0µL (4.10µg) ATIII + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
4. 2.0µL (1.62µg) FIXa + 2.0µL (4.10µg) ATIII + 11µL Tris/NaCl pH8 + 5µL 5X Sample 
Buffer 
5. [(2.0µL (4.10µg) ATIII + 1µg (3µL) Heparin) 15’ at RT, + 2.0µL FIXa + 8µL Tris/NaCl 
pH8] 30’ at RT, + 5µL 5X Sample Buffer] 
6. [(2.0µL (4.10µg) ATIII + 1µg (3µL) Protamine Sulfate) 15’ at RT, + 2.0µL (1.62µg) 
FIXa + 8µL Tris/NaCl pH8] 30’ at RT, + 5µL 5X Sample Buffer] 
7. [(2.0µL (4.10µg) ATIII + 0.07µg (3µL) Spermine) 15’ at RT, + 2.0µL (1.62µg) FIXa + 
8µL Tris/NaCl pH8] 30’ at RT, + 5µL 5X Sample Buffer] 
8. [(2.0µL (4.10µg) ATIII + 0.7µg (3µL) Spermine) 15’ at RT, + 2.0µL (1.62µg) FXIa + 
8µL Tris/NaCl pH8] 30’ at RT, + 5µL 5X Sample Buffer] (0.1 Concentration of 
Spemine) 
9. [(2.0µL (4.10µg) ATIII + 0.05µg (3µL) Spermidine) 15’ at RT, + 2.0µL (1.62µg) FIXa + 
8µL Tris/NaCl pH8] 30’ at RT, + 5µL 5X Sample Buffer] 
10. [(2.0µL (4.10µg) ATIII + 0.5µg (3µL) Spermidine) 15’ at RT, + 2.0µL (1.62µg) FIXa + 
8µL Tris/NaCl pH8] 30’ at RT, + 5µL 5X Sample Buffer] (0.1 Concentration of 
Spermidine)            
Photographs of the gels: 
Figure A 

















Table 1: Overall Protein Analysis Per Lane 




Figure C: Graphical Representation of Table 1.  
             
             











































IXa-ATIII 2.235 29.57 *ND 1.125 1.47 1.16 0.476 
Degradation *ND 0.816 *ND *ND *ND *ND *ND 
ATIII-M 45.89 35.18 49.74 49.08 50.12 50.98 55.44 
ATIII 0.57 0.909 0.836 0.27 0.62 0.453 0.463 
IXa 31.76 16.63 20.25 29.19 27.75 28.07 22.19 
Solvent 
Front- 19.54 16.9 29.18 20.34 20.05 19.34 21.43 
Table 2: IXa-ATIII Analysis Per Lane 
  


























































Table 3: Degradation Analysis Per Lane 
  














Degradation *ND 0.816 *ND *ND *ND *ND *ND 












































Table 4: ATIII-M Analysis Per Lane 
  














ATIII-M 45.89 35.18 49.74 49.08 50.12 50.98 55.44 
 
 








































Table 5: ATIII Analysis Per Lane 
  


























































Table 6: IXa Analysis Per Lane 
  


























































Table 7: Solvent Front Analysis Per Lane 
  




















Figure I: Graphical Representation of Table  






































Table 8:  Overall Protein Analysis Per Lane 
  














IXa-ATIII 2.299 29.28 *ND 1.05 0.95 0.69 0.973 
Degradation *ND 1.091 *ND *ND *ND *ND *ND 
ATIII-M 46.93 38.21 56.65 49.77 50.08 50.4 56.11 
ATIII 0.738 0.627 0.867 0.981 0.78 0.482 0.556 
IXa 32.95 14.9 13.16 30.13 29.63 28.57 20.77 
Solvent 
Front 17.09 15.89 29.33 18.08 18.57 19.86 21.59 
 
*ND= Not Detected 
 
 
































Table 9: IXa-ATIII Analysis Per Lane 
  














IXa-ATIII 2.299 29.28 *ND 1.05 0.95 0.69 0.973 








































Table 10: Degradation Analysis Per Lane 
  














Degradation *ND 1.091 *ND *ND *ND *ND *ND 





































































































ATIII-M 46.93 38.21 56.65 49.77 50.08 50.4 56.11 
 
Table 12: ATIII Analysis Per Lane 
  
























































Table 13: IXa Analysis Per Lane 
  

























































Table 14: Solvent Front Analysis Per Lane 
  



















Figure P: Graphical Representation of Table 14 
             
             


























































































IXa-ATIII 2.232 29.57 0 1.125 1.47 1.16 0.476 
IXa-ATIII 2.299 29.28 0 1.05 0.95 0.69 0.973 
P Values: 
IXa-ATIII 
    1.62µg IXa and 4.10µg ATIII 1.00µg H 
Mean 2.2655 29.425 
Variance 0.0022445 0.04205 
t Stat -152.1540616 
 P(T<=t) one-tail 0.002091993 
 t Critical one-tail 6.313751514 
 P(T<=t) two-tail 0.004183987 
 t Critical two-tail 12.70620473  
     1.62µg IXa and 4.10µg ATIII 1.00µg PS 
Mean 2.2655 0 
Variance 0.0022445 0 
t Stat 67.62686567 
 P(T<=t) one-tail 0.004706513 
 t Critical one-tail 6.313751514 
 P(T<=t) two-tail 0.009413025 
 t Critical two-tail 12.70620473  
     1.62µg IXa and 4.10µg ATIII 0.07µg SPM 
Mean 2.2655 1.0875 
Variance 0.0022445 0.0028125 
t Stat 16.5915493 
 P(T<=t) one-tail 0.019161881 
 t Critical one-tail 6.313751514 
 P(T<=t) two-tail 0.038323761 
 t Critical two-tail 12.70620473  
     1.62µg IXa and 4.10µg ATIII 0.7µg SPM 
Mean 2.2655 1.21 
Variance 0.0022445 0.1352 
t Stat 3.596252129 
 P(T<=t) one-tail 0.086330601 
 t Critical one-tail 6.313751514 
 P(T<=t) two-tail 0.172661202 
 t Critical two-tail 12.70620473  
     1.62µg IXa and 4.10µg ATIII 0.05µg SPD 
Mean 2.2655 0.925 
Variance 0.0022445 0.11045 
t Stat 4.99255121 
 P(T<=t) one-tail 0.062924282 
 t Critical one-tail 6.313751514 
 P(T<=t) two-tail 0.125848564 
 t Critical two-tail 12.70620473  
     1.62µg IXa and 4.10µg ATIII 0.5µg SPD 
Mean 2.2655 0.7245 
Variance 0.0022445 0.1235045 
t Stat 7.16744186 
 P(T<=t) one-tail 0.044125687 
 t Critical one-tail 6.313751514 
 P(T<=t) two-tail 0.088251374 
 t Critical two-tail 12.70620473  
 
PS- inhibits formation of the IXa-ATIII complex and the SPM and SPD both inhibit the same 
























































The Effects of Heparin, Protamine Sulfate, Spermine, and Spermidine on 














1. 5µL Molecular Weight Markers+ 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
2. 2.0µL (1.75µg) FXa + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
3. 2.0µL (4.10µg) ATIII + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
4. 2.0µL (1.75µg) FXa + 2.0µL (4.10µg) ATIII + 11µL Tris/NaCl pH8 + 5µL 5X Sample 
Buffer 
5. [(2.0µL (4.10µg) ATIII + 1µg (3µL) Protamine Sulfate) 15’ at RT, + 2.0µL (1.75µg) FXa 
+ 8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
6.  [(2.0µL (4.10µg) ATIII + 1µg (3µL) Heparin) 15’ at RT, + 1.0µL (1.75µg) FXa + 8µL 
Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
7.  [(2.0µL (4.10µg) ATIII + 0.07µg (3µL) Spermine) 15’ at RT, + 2.0µL (1.75µg) FXa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
8. [(2.0µL (4.10µg) ATIII + 0.7µg (3µL) Spermine) 15’ at RT, + 2.0µL (1.75µg) FXa + 8µL 
Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
9. [(2.0µL (4.10µg) ATIII + 0.05µg (3µL) Spermidine) 15’ at RT, + 2.0µL (1.75µg) FXa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
10. [(2.0µL (4.10µg) ATIII + 0.5µg (3µL) Spermidine) 15’ at RT, + 2.0µL (1.75µg) FXa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
 
Pictures of Each Gel: 
Figure A 
             
             
             
             
             
             















             
             
             
             




















Gel 1 will be analyzed first, followed by Gel 2, 3, and 4. 
Table 1: Overall Protein Analysis Per Lane 
*ND=Not Detected 
  














Primary Alpha 37.13 22.9 42.14 39.8 36.2 37.3 28.4 
Primary Beta 28.75 27.4 32.63 29.1 25.9 28.1 21.1 
Secondary 
Alpha *ND *ND *ND *ND *ND *ND *ND 
Secondary 
Beta *ND *ND *ND *ND *ND *ND *ND 
Tertiary Alpha 0.786 0.37 0.357 0.459 0.36 0.647 0.664 
Tertiary Beta 1.05 0.646 0.125 0.615 0.693 0.479 0.414 
ATIIIM 1.92 1.88 15.65 2.861 1.66 2.39 3.59 
ATIII 29 35.28 7.84 25.6 34 30.01 44.04 
Xa Alpha 0.832 0.986 0.87 0.66 0.471 0.469 1.53 
Xa Beta 0.535 1.364 0.396 0.937 0.702 0.663 0.277 
Solvent Front *ND *ND *ND *ND *ND *ND *ND 
PS Degradation *ND 9.1 *ND *ND *ND *ND *ND 




Standard  1.777999 
Deviation 
     
Error 
  
Figure C: Graphical Representation of Table 1 
             
             
             
             

















Table 2: Primary Alpha [Xa-ATIII] Analysis Per Lane 
  



















Figure D: The Graphical Representation of Table 2 
             
             
             






































Figure E: Graphical Representation of Table 3 
             
             





































 1.75µg Xa & 4.10µg 
ATIII 
1.0µg 









Primary Beta 28.75 27.4 32.63 29.1 25.9 28.1 21.1 
 
 




































             




















Tertiary Alpha 0.786 0.37 0.357 0.459 0.36 0.647 0.664 
Table 5: Tertiary Beta [Xa-ATIII] Analysis Per Lane 
 
 
Figure G: Graphical Representation of Table 5 
             
             





































 1.75µg Xa & 4.10µg 
ATIII 
1.0µg 









Tertiary Beta 1.05 0.646 0.125 0.615 0.693 0.479 0.414 
Table 6: ATIII-M Analysis Per Lane 
 
  
 1.75µg Xa & 4.10µg 
ATIII 
1.0µg 









ATIIIM 1.92 1.88 15.65 2.861 1.66 2.39 3.59 
 
Figure H: Graphical Representation of Table 6 
             
             
             
             
             
             
             
             































Table 7: ATIII Analysis Per Lane 
 
 
Figure I: Graphical Representation of Table 7 
             
             
             
             


















































ATIII 29 35.28 7.84 25.6 34 30.01 44.04 





Figure J: Graphical Representation of Table 8 
             
             



































 1.75µg Xa & 4.10µg 
ATIII 
1.0µg 









Xa Alpha 0.832 0.986 0.87 0.66 0.471 0.469 1.53 




Figure K: Graphical Representation of Table 9 
             
             
             
















































Xa Beta 0.535 1.364 0.396 0.937 0.702 0.663 0.277 
Table 10: PS Degradation Analysis Per Lane 
*ND= Not Detected 
 
 





















































PS Degradation *ND 9.1 *ND *ND *ND *ND *ND 
Gel 2 
Table 11: Overall Protein Analysis Per Lane 
*ND= Not Detected 
 
Figure M: Graphical Representation of Table 11 
 
             
             
             
             
             


























Primary Alpha 36.2 24 39.2 35.8 33.7 37.4 29.4 
Primary Beta 28.1 26.9 32.7 30.5 28.6 26.9 22 
Secondary 
Alpha *ND *ND *ND *ND *ND *ND *ND 
Seconday Beta *ND *ND *ND *ND *ND *ND *ND 
Tertiary Alpha 1.34 1.225 0.963 1.38 1.72 0.539 1.18 
Tertiary Beta 1.32 0.452 0.954 2.25 1.22 1.16 0.72 
ATIIIM 2.06 2.46 17.7 2.12 0.24 2.98 1.39 
ATIII 30 36.9 7.3 23.3 31.6 29.7 42.5 
Xa Alpha 0.3456 0.598 0.88 1.75 0.974 0.493 2.15 
Xa Beta 0.697 0.912 0.373 2.98 0.971 0.88 0.781 
Solvent Front *ND 1.27 *ND *ND *ND *ND *ND 
PS Degradation *ND 5.24 *ND *ND *ND *ND *ND 






     
Error 
 




Figure N: Graphical Representation of Table 12 
             



















































Primary Alpha 36.2 24 39.2 35.8 33.7 37.4 29.4 
Table 13: Primary Beta [Xa-ATIII] Analysis Per Lane 
 
  


















Figure O: Graphical Representations of Table 13 
             
             







































Figure P: Graphical Representation of Table 14 
 
             
             
















































Tertiary Alpha 1.34 1.225 0.963 1.38 1.72 0.539 1.18 
 






Figure Q: Graphical Representation of Table 15 
             




















































Table 16: ATIII-M Analysis Per Lane 
 
  














ATIIIM 2.06 2.46 17.7 2.12 0.24 2.98 1.39 
 
 
Figure R: Graphical Representation of Table 16 
             


































Table 17: ATIII Analysis Per Lane 
 
 






















































ATIII 30 36.9 7.3 23.3 31.6 29.7 42.5 


























































Xa Alpha 0.3456 0.598 0.88 1.75 0.974 0.493 2.15 
Table 19: Xa Beta Analysis Per Lane 
 
  














Xa Beta 0.697 0.912 0.373 2.98 0.971 0.88 0.781 
 
 







































Table 20:  Solvent Front Analysis Per Lane 
 
*ND= Not Detected 
 
 





















































Solvent Front *ND 1.27 *ND *ND *ND *ND *ND 
Table 21: PS Degradation Analysis Per Lane 
*ND- Not Detected 
  














PS Degradation *ND 5.24 *ND *ND *ND *ND *ND 
 
 












































Gels 3 and 4 have a slightly different lane set up than Gels 1 and 2 
1. 5µL Molecular Weight Markers+ 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
2. 2.0µL (1.75µg) FXa + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
3. 2.0µL (4.10µg) ATIII + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
4. 2.0µL (1.75µg) FXa + 2.0µL (4.10µg) ATIII + 11µL Tris/NaCl pH8 + 5µL 5X Sample 
Buffer 
5. [(2.0µL (4.10µg) ATIII + 1µg (3µL) Heparin) 15’ at RT, + 1.0µL (1.75µg) FXa + 8µL 
Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
6.  [(2.0µL (4.10µg) ATIII + 1µg (3µL) Protamine Sulfate) 15’ at RT, + 2.0µL (1.75µg) 
FXa + 8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
7. [(2.0µL (4.10µg) ATIII + 0.07µg (3µL) Spermine) 15’ at RT, + 2.0µL (1.75µg) FXa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
8. [(2.0µL (4.10µg) ATIII + 0.7µg (3µL) Spermine) 15’ at RT, + 2.0µL (1.75µg) FXa + 8µL 
Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
9. [(2.0µL (4.10µg) ATIII + 0.05µg (3µL) Spermidine) 15’ at RT, + 2.0µL (1.75µg) FXa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
10. [(2.0µL (4.10µg) ATIII + 0.5µg (3µL) Spermidine) 15’ at RT, + 2.0µL (1.75µg) FXa + 















Figure X: Gel 3 
 
 



























Gel 3:  
Table 22:  Overall Protein Per Lane 
*ND= Not Detected 
 
 





























SPD 0.5µg SPD 
Primary Alpha 30.4 30.5 14.6 32.5 33.2 31.3 29.5 
Primary Beta 24.6 26.6 25.3 27.5 26.5 27.4 25 
Secondary 
Alpha *ND *ND *ND *ND *ND *ND *ND 
Seconday 
Beta *ND *ND *ND *ND *ND *ND *ND 
Tertiary Alpha 0.458 0.508 0.644 0.474 1.19 0.527 0.147 
Tertiary Beta 0.619 0.219 1.25 0.372 1.32 0.422 0.071 
ATIIIM 1.84 11.5 1.6 2.29 0.928 1.28 0.938 
ATIII 40.5 28.4 36 33.8 33.2 37.5 42.8 
Xa Alpha 0.298 1.34 0.885 0.852 0.746 0.397 1.11 
Xa Beta 0.962 0.328 0.111 1.43 1.13 0.66 0.27 
Solvent Front 0.375 0.586 1.34 0.83 1.71 0.545 0.141 
PS 
Degradation *ND *ND 18.3 *ND *ND *ND *ND 


































































Alpha 30.4 30.5 14.6 32.5 33.2 31.3 29.5 
 
Table 24: Primary Beta [Xa-ATIII] Complex Analysis Per Lane 
 
 




















































Primary Beta 24.6 26.6 25.3 27.5 26.5 27.4 25 

























































Alpha 0.458 0.508 0.644 0.474 1.19 0.527 0.147 
Table 26: Tertiary Beta [IIa-ATIII] Complex Analysis Per Lane 
 
  














Tertiary Beta 0.619 0.219 1.25 0.372 1.32 0.422 0.071 
 
 






























































































ATIIIM 1.84 11.5 1.6 2.29 0.928 1.28 0.938 
Table 28: ATIII Analysis Per Lane 
 
  
























































Table 29: Xa Alpha Analysis Per Lane 
 
  
























































Table 30: Xa Beta Analysis Per Lane 
 
  














Xa Beta 0.962 0.328 0.111 1.43 1.13 0.66 0.27 
 
 
































































































Front 0.375 0.586 1.34 0.83 1.71 0.545 0.141 
Table 32:  PS Degradation Analysis Per Lane 

























































Degradation *ND *ND 18.3 *ND *ND *ND *ND 
Gel 4 
Table 33: Overall Protein Analysis Per Lane 
*ND= Not Detected 
  









SPD 0.5µg SPD 
Primary Alpha 28.4 30.8 11 30.2 29 30.9 25.7 
Primary Beta 23.7 26.6 23.5 27 24.1 25.5 23.6 
Secondary 
Alpha *ND *ND *ND *ND *ND *ND *ND 
Seconday 
Beta *ND *ND *ND *ND *ND *ND *ND 
Tertiary Alpha 0.15 0.141 0.269 0.783 2.72 0.425 0.241 
Tertiary Beta 0.229 0.114 0.872 0.89 1.78 0.498 0.18 
ATIIIM 0.768 12 0.907 2.564 3.08 1.17 1.24 
ATIII 44.4 28.7 34.2 34.4 33 40.4 47.5 
Xa Alpha 0.84 0.8 0.253 1.01 1 0.227 0.647 
Xa Beta 0.685 0.72 0.618 1.253 3.29 0.532 0.486 
Solvent Front 0.773 0.125 1.29 1.915 2.04 0.363 0.433 
PS 
Degradation *ND *ND 27.2 *ND *ND *ND *ND 






     
Error 
  





















Table 34: Primary Alpha [Xa-ATIII] Complex Analysis Per Lane 
 
  









SPM 0.05µg SPD 
0.5µg 
SPD 
Primary Alpha 28.4 30.8 11 30.2 29 30.9 25.7 
 
 








































Table 35: Primary Beta [Xa-ATIII] Complex Analysis Per Lane 
 
  









SPM 0.05µg SPD 
0.5µg 
SPD 









































Table 36: Tertiary Alpha [IIa-ATIII] Complex Analysis Per Lane 
 
 




















































Tertiary Alpha 0.15 0.141 0.269 0.783 2.72 0.425 0.241 
Table 37: Tertiary Beta [Xa-ATIII] Analysis Per Lane 
 
  














Tertiary Beta 0.229 0.114 0.872 0.89 1.78 0.498 0.18 
 
 






























































































ATIIIM 0.768 12 0.907 2.564 3.08 1.17 1.24 

























































ATIII 44.4 28.7 34.2 34.4 33 40.4 47.5 
Table 40: Xa Alpha Analysis Per Lane 
  
























































Table 41: Xa Beta Analysis Per Lane 
 
 
Figure SS: Graphical Representation of Table 41 
 
 
             
             
             
             
             
             
             
             
             
             








































Xa Beta 0.685 0.72 0.618 1.253 3.29 0.532 0.486 
Table 42: Solvent Front Analysis Per Lane 
  














Solvent Front 0.773 0.125 1.29 1.915 2.04 0.363 0.433 
 
 






































Table 43: PS Degradation Analysis Per Lane 

























































Degradation *ND *ND 27.2 *ND *ND *ND *ND 
Tables used to determine P Values 
  














Primary Alpha 37.13 22.9 42.14 39.8 36.2 37.3 28.4 
Primary Alpha 36.2 24 39.2 35.8 33.7 37.4 29.4 
Primary Alpha 30.4 14.6 30.5 32.5 33.2 31.3 29.5 
Primary Alpha 28.4 11 30.8 30.2 29 30.9 25.7 
        
  














Primary Beta 28.75 27.4 32.63 29.1 25.9 28.1 21.1 
Primary Beta 28.1 26.9 32.7 30.5 28.6 26.9 22 
Primary Beta 24.6 25.3 26.6 27.5 26.5 27.4 25 
Primary Beta 23.7 23.5 26.6 27 24.1 25.5 23.6 
        
  














Secondary Alpha *ND *ND *ND *ND *ND *ND *ND 
Secondary Alpha *ND *ND *ND *ND *ND *ND *ND 
Secondary Alpha *ND *ND *ND *ND *ND *ND *ND 
Secondary Alpha *ND *ND *ND *ND *ND *ND *ND 
        
  














Secondary Beta *ND *ND *ND *ND *ND *ND *ND 
Secondary Beta *ND *ND *ND *ND *ND *ND *ND 
Secondary Beta *ND *ND *ND *ND *ND *ND *ND 
Secondary Beta *ND *ND *ND *ND *ND *ND *ND 
        
  














Tertiary Alpha 0.786 0.37 0.357 0.459 0.36 0.647 0.664 
Tertiary Alpha 1.34 1.225 0.963 1.38 1.72 0.539 1.18 
Tertiary Alpha 0.458 0.644 0.508 0.474 1.19 0.527 0.147 
Tertiary Alpha 0.15 0.269 0.141 0.783 2.72 0.425 0.241 
        
  














Tertiary Beta 1.05 0.646 0.125 0.615 0.693 0.479 0.414 
Tertiary Beta 1.32 0.452 0.954 2.25 1.22 1.16 0.72 
Tertiary Beta 0.619 1.25 0.219 0.372 1.32 0.422 0.071 
Tertiary Beta 0.229 0.872 0.114 0.89 1.78 0.498 0.18 
 
P Values for Primary Alpha 
Primary Alpha 
  
      1.75µg Xa & 4.10µg ATIII 1.0µg PS 
Mean 33.0325 18.125 
Variance 18.404225 40.16916667 
Observations 4 4 
t Stat 13.42406433 
 P(T<=t) one-tail 0.000446869 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.000893738 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 1.0µg Heparin 
Mean 33.0325 35.66 
Variance 18.404225 34.9224 
Observations 4 4 
t Stat -2.600012051 
 P(T<=t) one-tail 0.040187493 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.080374986 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.07µg SPM 
Mean 33.0325 34.575 
Variance 18.404225 17.41583333 
Observations 4 4 
t Stat -2.294822268 
 P(T<=t) one-tail 0.052744123 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.105488247 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.7µg SPM 
Mean 33.0325 33.025 
Variance 18.404225 8.9225 
Observations 4 4 
t Stat 0.006638929 
 P(T<=t) one-tail 0.497559868 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.995119737 
 
t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.05µg SPD 
Mean 33.0325 34.225 
Variance 18.404225 13.04916667 
Observations 4 4 
t Stat -2.450971358 
 P(T<=t) one-tail 0.045800097 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.091600195 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.5µg SPD 
Mean 33.0325 28.25 
Variance 18.404225 3.136666667 
Observations 4 4 
t Stat 2.65069069 
 P(T<=t) one-tail 0.038474178 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.076948356 
























P Values for Primary Beta 
Primary Beta 
  
      1.75µg Xa & 4.10µg ATIII 1.0µg PS 
Mean 26.2875 25.775 
Variance 6.297291667 3.1025 
Observations 4 4 
t Stat 1.072162632 
 P(T<=t) one-tail 0.181113116 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.362226232 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 1.0µg Heparin 
Mean 26.2875 29.6325 
Variance 6.297291667 12.262225 
Observations 4 4 
t Stat -5.891510707 
 P(T<=t) one-tail 0.004880404 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.009760809 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.07µg SPM 
Mean 26.2875 28.525 
Variance 6.297291667 2.53583333 
Observations 4 4 
t Stat -3.413189216 
 P(T<=t) one-tail 0.021026117 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.042052234 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.7µg SPM 
Mean 26.2875 26.275 
Variance 6.297291667 3.4425 
Observations 4 4 
t Stat 0.012426756 
 P(T<=t) one-tail 0.49543267 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.990865341 
 
t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.05µg SPD 
Mean 26.2875 26.975 
Variance 6.297291667 1.20916667 
Observations 4 4 
t Stat -0.716383119 
 P(T<=t) one-tail 0.262743311 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.525486621 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.5µg SPD 
Mean 26.2875 22.925 
Variance 6.297291667 2.9825 
Observations 4 4 
t Stat 1.636243759 
 P(T<=t) one-tail 0.100153875 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.200307749 
























P Values for Tertiary Alpha 
Tertiary Alpha 
  
      1.75µg Xa & 4.10µg ATIII 1.0µg PS 
Mean 0.6835 0.627 
Variance 0.258990333 0.184035333 
Observations 4 4 
t Stat 0.41514482 
 P(T<=t) one-tail 0.35296989 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.705939779 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 1.0µg Heparin 
Mean 0.6835 0.49225 
Variance 0.258990333 0.12117425 
Observations 4 4 
t Stat 1.551052084 
 P(T<=t) one-tail 0.109340383 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.218680766 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.07µg SPM 
Mean 0.6835 0.774 
Variance 0.258990333 0.185514 
Observations 4 4 
t Stat -0.454057344 
 P(T<=t) one-tail 0.34031223 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.68062446 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.7µg SPM 
Mean 0.6835 1.4975 
Variance 0.258990333 0.977491667 
Observations 4 4 
t Stat -1.284878464 
 P(T<=t) one-tail 0.144527018 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.289054036 
 
t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.05µg SPD 
Mean 0.6835 0.5345 
Variance 0.258990333 0.008241 
Observations 4 4 
t Stat 0.638977112 
 P(T<=t) one-tail 0.284140028 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.568280056 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.5µg SPD 
Mean 0.6835 0.558 
Variance 0.258990333 0.22251 
Observations 4 4 
t Stat 1.513724567 
 P(T<=t) one-tail 0.113657605 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.227315209 
























P Values for Tertiary Beta 
Tertiary Beta 
  
      1.75µg Xa & 4.10µg ATIII 1.0µg PS 
Mean 0.8045 0.805 
Variance 0.230540333 0.117468 
Observations 4 4 
t Stat -0.001317521 
 P(T<=t) one-tail 0.499515742 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.999031484 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 1.0µg Heparin 
Mean 0.8045 0.353 
Variance 0.230540333 0.162754 
Observations 4 4 
t Stat 2.653599311 
 P(T<=t) one-tail 0.03837861 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.07675722 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.07µg SPM 
Mean 0.8045 1.03175 
Variance 0.230540333 0.70439225 
Observations 4 4 
t Stat -0.678664488 
 P(T<=t) one-tail 0.273007483 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.546014966 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.7µg SPM 
Mean 0.8045 1.25325 
Variance 0.230540333 0.19896892 
Observations 4 4 
t Stat -1.041227028 
 P(T<=t) one-tail 0.187151948 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.374303896 
 
t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.05µg SPD 
Mean 0.8045 0.63975 
Variance 0.230540333 0.12133625 
Observations 4 4 
t Stat 0.958885578 
 P(T<=t) one-tail 0.20417735 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.4083547 
 t Critical two-tail 3.182446305   
      1.75µg Xa & 4.10µg ATIII 0.5µg SPD 
Mean 0.8045 0.34625 
Variance 0.230540333 0.08256025 
Observations 4 4 
t Stat 3.330132065 
 P(T<=t) one-tail 0.022357402 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.044714803 










































The Effects of Heparin, Protamine Sulfate, Spermine, and Spermidine on 














1. 5µL Molecular Weight Markers+ 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
2. 2.0µL (0.762µg) FXIa + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
3. 2.0µL (4.10µg) ATIII + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
4. 2.0µL (0.762µg) FXIa + 2.0µL (4.10µg) ATIII + 11µL Tris/NaCl pH8 + 5µL 5X Sample 
Buffer 
5. [(2.0µL (4.10µg) ATIII + 1µg (3µL) Heparin) 15’ at RT, + 1.0µL (0.762µg) FXIa + 8µL 
Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
6. [(2.0µL (4.10µg) ATIII + 1µg (3µL) Protamine Sulfate) 15’ at RT, + 2.0µL (0.762µg) 
FXIa + 8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
7. [(2.0µL (4.10µg) ATIII + 0.07µg (3µL) Spermine) 15’ at RT, + 2.0µL (0.762µg) FXIa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
8. [(2.0µL (4.10µg) ATIII + 0.7µg (3µL) Spermine) 15’ at RT, + 2.0µL (0.762µg) FXIa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
9. [(2.0µL (4.10µg) ATIII + 0.05µg (3µL) Spermidine) 15’ at RT, + 2.0µL (0.762µg) FXIa 
+ 8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
10. [(2.0µL (4.10µg) ATIII + 0.5µg (3µL) Spermidine) 15’ at RT, + 2.0µL (0.762 µg) FXIa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
 
Pictures of Each Gel: 
Figure A 
             
             
             
             
             
             



































             
             
             
             
Gel 1 analysis will be first, followed by Gel 2,3, and 4, analysis, then a summary. 
Table 1: Overall Protein Analysis Per Lane 
  














[XIa-(ATIII)2] 0.9 2.4 *ND *ND *ND *ND *ND 
[XIa-ATIII] 12.1 19.5 7.1 8.1 8.7 7.2 5 
XIa 29.9 31.9 35.2 41.5 40 40 25.2 
ATIII 52.8 45.4 43.6 47.4 47.6 49.5 67.2 
Solvent 
Front 4.3 0.8 14 3.1 3.7 3.4 2.6 
 
*ND= Not Detected 
 




Standard  3.38892 
Deviation 





Figure C: Graphical Representation of Table 1 
             
             
             
             
             
             





















Table 2: [XIa-(ATIII)2] Analysis Per Lane 
  




















Figure D: Graphical Representation of Table 2 
             
             
             
             


































Table 3: [XIa-ATIII] Analysis Per Lane 
  


















Figure E: Graphical Representation of Table 3 
             
             
             
             
             
             































Table 4: XIa Per Lane Analysis 
  














XIa 29.9 31.9 35.2 41.5 40 40 25.2 
 
 
Figure F: Graphical Representation of Table 4 
             
             
             
             
             
             

































Table 5: ATIII Per Lane Analysis 
  














ATIII 52.8 45.4 43.6 47.4 47.6 49.5 67.2 
 
 
Figure G: Graphical Representation of Table 5 
             
             
             
             



































Table 6: Solvent Front Analysis Per Lane 
  















Front 4.3 0.8 14 3.1 3.7 3.4 2.6 
 
Figure H: Graphical Representation of Table 6 
             
             
             
             




































Table 7:  Overall Protein Analysis Per Lane 
  














[XIa-(ATIII)2] 0.4 1.7 *ND *ND *ND *ND *ND 
[XIa-ATIII] 11.6 19.4 6.7 7.6 7.5 6.6 4.2 
XIa 30.3 33.9 35.5 42.1 40.6 40.6 27.3 
ATIII 53.5 44.1 45.1 47 48.6 50.3 65.9 
Solvent 
Front 4.2 0.9 12.6 3.3 3.4 2.5 2.6 
 





Standard  3.444179 
Deviation 



































Table 8:  [XIa-(ATIII)2] Analysis Per Lane 
 








































 0.762µg XIa & 












(ATIII)2] 0.4 1.7 *ND *ND *ND *ND *ND 
Table 9: [XIa-ATIII] Analysis Per Lane 
  
 0.762µg XIa & 4.10µg 
ATIII 
1.0µg 









[XIa-ATIII] 11.6 19.4 6.7 7.6 7.5 6.6 4.2 
 
 







































Table 10: XIa Analysis Per Lane 
  














XIa 30.3 33.9 35.5 42.1 40.6 40.6 27.3 
 
 






































Table 11 ATIII Analysis Per Lane 
  














ATIII 53.5 44.1 45.1 47 48.6 50.3 65.9 
 








































Table 12:  Solvent Front Analysis Per Lane 
  
 0.762µg XIa & 4.10µg 
ATIII 
1.0µg 










Front 4.2 0.9 12.6 3.3 3.4 2.5 2.6 
 
 























































































Table 12: Overall Protein Analysis Per Lane 
 
  














[XIa-(ATIII)2] 0.6 4.8 *ND *ND *ND *ND *ND 
[XIa-ATIII] 11 16.6 4.1 4.8 4.4 1.7 1.6 
XIa 28.4 10.8 31.2 32.8 41.1 66.9 81.1 
ATIII 54.3 67.4 37 59.9 51.8 28.9 7.9 
Solvent 
Front 5.8 0.3 27.7 2.5 2.6 2.4 9.4 



































Standard  4.069882 
Deviation 




Table 13: [XIa-(ATIII)2] Analysis Per Lane 
  













(ATIII)2] 0.6 4.8 *ND *ND *ND *ND 
*ND= Not Detected 
 








































Table 14: [XIa-ATIII] Analysis Per Lane 
  














[XIa-ATIII] 11 16.6 4.1 4.8 4.4 1.7 1.6 
 
 








































Table 15: XIa Analysis Per Lane 
  














XIa 28.4 10.8 31.2 32.8 41.1 66.9 81.1 
 
 









































Table 16: ATIII Analysis Per Lane 
  














ATIII 54.3 67.4 37 59.9 51.8 28.9 7.9 
 









































Table 17: Solvent Front Analysis Per Lane 
  















Front 5.8 0.3 27.7 2.5 2.6 2.4 9.4 
 
 









































Table 18:  Overall Protein Analysis Per Lane 
  















(ATIII)2] 0.7 5.1 *ND *ND *ND *ND *ND 
[XIa-ATIII] 12.1 18.7 5.1 5.6 3.3 2 1.6 
XIa 28.8 11.2 32.9 36.8 39.4 60.6 76.6 
ATIII 49.9 64 39.5 53.8 52.5 30.8 10.1 
Solvent 
Front 8.4 1.3 22.5 3.8 4.8 6.6 11.7 





Standard  3.764312 
Deviation 


































Table 19: [XIa-(ATIII)2] Analysis Per Lane  
  











SPD 0.5µg SPD 
[XIa-
(ATIII)2] 0.7 5.1 *ND *ND *ND *ND *ND 
 
*ND= Not Detected 
 
 






































Table 20: [XIa-ATIII] Analysis Per Lane 
  











SPD 0.5µg SPD 












































Table 21: XIa Analysis Per Lane 
  











SPD 0.5µg SPD 












































Table 22:  ATIII Analysis Per Lane 
  











SPD 0.5µg SPD 











































Table 23: Solvent Front Analysis Per Lane 
  











SPD 0.5µg SPD 
Solvent 
Front 8.4 1.3 22.5 3.8 4.8 6.6 11.7 
 
 

























P Value Tables: 



















(ATIII)2] 0.9 2.4 *ND *ND *ND *ND *ND 
[XIa-
(ATIII)2] 0.4 1.7 *ND *ND *ND *ND *ND 
[XIa-
(ATIII)2] 0.6 4.8 *ND *ND *ND *ND *ND 
[XIa-
(ATIII)2] 0.7 5.1 *ND *ND *ND *ND *ND 
        
 














[XIa-ATIII] 12.1 19.5 7.1 8.1 8.7 7.2 5 
[XIa-ATIII] 11.6 19.4 6.7 7.6 7.5 6.6 4.2 
[XIa-ATIII] 11 16.6 4.1 4.8 4.4 1.7 1.6 
[XIa-ATIII] 12.1 18.7 5.1 5.6 3.3 2 1.6 
        
 














XIa 29.9 31.9 35.2 41.5 40 40 25.2 
XIa 30.3 33.9 35.5 42.1 40.6 40.6 27.3 
XIa 28.4 10.8 31.2 32.8 41.1 66.9 81.1 
XIa 28.8 11.2 32.9 36.8 39.4 60.6 76.6 
        
 














ATIII 52.8 45.4 43.6 47.4 47.6 49.5 67.2 
ATIII 53.5 44.1 45.1 47 48.6 50.3 65.9 
ATIII 54.3 67.4 37 59.9 51.8 28.9 7.9 
ATIII 49.9 64 39.5 53.8 52.5 30.8 10.1 
        
 















Front 4.3 0.8 14 3.1 3.7 3.4 2.6 
Solvent 
Front 4.2 0.9 12.6 3.3 3.4 2.5 2.6 
Solvent 
Front 5.8 0.3 27.7 2.5 2.6 2.4 9.4 
Solvent 
Front 8.4 1.3 22.5 3.8 4.8 6.6 11.7 
P Values for [XIa-(ATIII)2] Complex 
[XIa-(ATIII)2] 
  P Values for [XIa-
(ATIII)2] 
     0.762µg XIa & 4.10µg ATIII 1.0µg Heparin 
Mean 0.65 3.5 
Variance 0.043333333 2.9 
Observations 4 4 
P(T<=t) one-tail 0.021288364 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.042576728 
 t Critical two-tail 3.182446305  
      0.762µg XIa & 4.10µg ATIII 1.0µg PS 
Mean 0.65 0 
Variance 0.043333333 0 
t Stat 6.244997998 
 P(T<=t) one-tail 0.004141335 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.008282669 
 t Critical two-tail 3.182446305  
      0.762µg XIa & 4.10µg ATIII 0.07µg SPM 
Mean 0.65 0 
Variance 0.043333333 0 
t Stat 6.244997998 
 P(T<=t) one-tail 0.004141335 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.008282669 
 t Critical two-tail 3.182446305  
      0.762µg XIa & 4.10µg ATIII 0.7µg SPM 
Mean 0.65 0 
Variance 0.043333333 0 
t Stat 6.244997998 
 P(T<=t) one-tail 0.004141335 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.008282669 
 t Critical two-tail 3.182446305  
      0.762µg XIa & 4.10µg ATIII 0.05 SPDµg PS 
Mean 0.65 0 
Variance 0.043333333 0 
t Stat 6.244997998 
 
P(T<=t) one-tail 0.004141335 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.008282669 
 t Critical two-tail 3.182446305  
      0.762µg XIa & 4.10µg ATIII 0.5µg SPD 
Mean 0.65 0 
Variance 0.043333333 0 
t Stat 6.244997998 
 P(T<=t) one-tail 0.004141335 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.008282669 


































P Values for [XIa-ATIII] 
[XIa-ATIII] 
     0.762µg XIa & 4.10µg ATIII 1.0µg Heparin 
Mean 11.7 18.55 
Variance 0.273333333 1.816666667 
t Stat -14.10548348 
 P(T<=t) one-tail 0.000385899 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.000771799 
 t Critical two-tail 3.182446305  
   0.762µg XIa & 4.10µg ATIII 1.0µg PS 
Mean 11.7 5.75 
Variance 0.273333333 1.956666667 
t Stat 10.29284428 
 P(T<=t) one-tail 0.000977846 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.001955692 
 t Critical two-tail 3.182446305  
   0.762µg XIa & 4.10µg ATIII 0.07µg SPM 
Mean 11.7 6.525 
Variance 0.273333333 2.489166667 
t Stat 7.597502721 
 P(T<=t) one-tail 0.002365834 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.004731668 
 t Critical two-tail 3.182446305  
   0.762µg XIa & 4.10µg ATIII 0.7µg SPM 
Mean 11.7 5.975 
Variance 0.273333333 6.4625 
t Stat 4.640091621 
 P(T<=t) one-tail 0.009432442 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.018864884 
 t Critical two-tail 3.182446305  
   0.762µg XIa & 4.10µg ATIII 0.05µg SPD 
Mean 11.7 4.375 
Variance 0.273333333 8.575833333 
t Stat 5.303945751 
 P(T<=t) one-tail 0.006541575 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.01308315 
 t Critical two-tail 3.182446305  
   0.762µg XIa & 4.10µg ATIII 0.5µg SPD 
Mean 11.7 3.1 
Variance 0.273333333 3.106666667 
t Stat 10.57252749 
 P(T<=t) one-tail 0.000903839 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.001807678 




[XIa-(ATIII)2] and [XIa-ATIII] are formed upon preincubating XIa and ATIII at room 
temperature for thirty minutes.  Corresponding to 0.4% of total protein per lane, this is increased 
in the presence of 3ug of Heparin. 
However, upon addition of 3ug of Protamine Sulfate, 0.07ug of Spermine, 0.7ug Spermine, 
0.05ug Spermidine, and 0.5ug Spermidine, to the Xia prior to the addition of ATIII prevented or 
inhibited the formation of the [XIa-ATIII] complex. 
Furthermore, 10.7% of the protein in the lane is represented by a major degradation of [XIa-
ATIII].  The band increases to 19.4% in the presence of Heparin and is decreased to 5.9% with 
Protamine Sulfate, 6.8% with 0.07ug Spermine, 7.2% with 0.7 Spermine, 6.1% with 0.05ug 














































The Effects of Heparin, Protamine Sulfate, Sperimine, and Spermidine 















1. 5µL Molecular Weight Markers+ 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
2. 2.0µL (2.45µg) FIIa + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
3. 2.0µL (4.10µg) ATIII + 13µL Tris/NaCl pH8 + 5µL 5X Sample Buffer 
4. 2.0µL (2.45µg) FIIa + 2.0µL (4.10µg) ATIII + 11µL Tris/NaCl pH8 + 5µL 5X Sample 
Buffer 
5. [(2.0µL (4.10µg) ATIII + 1µg (3µL) Heparin) 15’ at RT, + 2.0µL (2.45µg) FIIa + 8µL 
Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
6. [(2.0µL (4.10µg) ATIII + 1µg (3µL) Protamine Sulfate) 15’ at RT, + 2.0µL (2.45µg) FIIa 
+ 8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
7. [(2.0µL (4.10µg) ATIII + 0.07µg (3µL) Spermine) 15’ at RT, + 2.0µL (2.45µg) FIIa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
8. [(2.0µL (4.10µg) ATIII + 0.7µg (3µL) Spermine) 15’ at RT, + 2.0µL (2.45µg) FIIa + 8µL 
Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
9. [(2.0µL (4.10µg) ATIII + 0.05µg (3µL) Spermidine) 15’ at RT, + 2.0µL (2.45µg) FIIa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
10. [(2.0µL (4.10µg) ATIII + 0.5µg (3µL) Spermidine) 15’ at RT, + 2.0µL (2.45µg) FIIa + 
8µL Tris/NaCl pH8] 60’ at RT, + 5µL 5X Sample Buffer] 
*Gels 1 and 2 were thrown out for inaccuracy 
Pictures of Each Gel: 
Gel 3 and 4 
 











































Table 1: Overall Protein Analysis Per Lane 
*ND= Not Detected 
  














Alpha [IIa-ATIII] 13.8 6.4 37.7 34.2 24.7 24.8 51.9 
Beta [IIa-ATIIII] 36.7 21.7 30.3 39.1 36.4 42.1 32.1 
Gamma [IIa-
ATIII] 12.3 34.2 4.24 6.9 9.36 8.27 2.59 
ATIIIM 8.41 4.48 1.31 0.64 0.96 0.23 0.92 
ATIII 5.76 5.74 3.69 4.74 5.85 3.93 7.43 
IIa 23 27.5 19.2 14.4 22.8 20.7 5.04 
Solvent Front *ND *ND 3.64 *ND *ND *ND *ND 




Standard  2.024298 
Deviation 































Table 2: Alpha [IIa-ATIII] Complex Analysis Per Lane 
  














Alpha [IIa-ATIII] 13.8 6.4 37.7 34.2 24.7 24.8 51.9 
 
 








































Table 3: Beta [IIa-ATIII] Complex Analysis Per Lane 
  














Beta [IIa-ATIIII] 36.7 21.7 30.3 39.1 36.4 42.1 32.1 
 
 








































Table 4: Gamma [IIa-ATIII] Complex Analysis Per Lane 
  















ATIII] 12.3 34.2 4.24 6.9 9.36 8.27 2.59 
 
 








































Table 5: ATIII-M Analysis Per Lane 
  














ATIIIM 8.41 4.48 1.31 0.64 0.96 0.23 0.92 
 
 









































Table 6: ATIII Analysis Per Lane 
  














ATIII 5.76 5.74 3.69 4.74 5.85 3.93 7.43 
 
 







































Table 7: IIa Analysis Per Lane 
  














IIa 23 27.5 19.2 14.4 22.8 20.7 5.04 
 









































Table 8: Solvent Front Analysis Per Lane 
  














Solvent Front *ND *ND 3.64 *ND *ND *ND *ND 
 
*ND= Not Detected 
 








































Table 9: Overall Protein Analysis Per Lane 
  














Alpha [IIa-ATIII] 13.7 5.88 35.7 32.9 24 23.2 54.1 
Beta [IIa-ATIIII] 42.1 21 30.6 39.8 39 41.5 30.9 
Gamma [IIa-
ATIII] 11.8 33 3.65 6.92 6.21 7.75 2 
ATIIIM 2.82 4.47 0.8 0.54 2.04 0.44 0.49 
ATIII 3.73 5.16 2.8 4.12 5.08 3.75 5.93 
IIa 25.9 30.5 20.5 15.7 23.7 23.4 6.52 
Solvent Front *ND *ND 5.9 *ND *ND *ND *ND 






     
Error 
  
*ND= Not Detected 
 



























Table 10: Alpha [IIa-ATIII] Complex Analysis Per Lane 
  














Alpha [IIa-ATIII] 13.7 5.88 35.7 32.9 24 23.2 54.1 
 
 







































Table 11: Beta [IIa-ATIII] Complex Analysis Per Lane 
  














Beta [IIa-ATIIII] 42.1 21 30.6 39.8 39 41.5 30.9 
 
 








































Table 12:  Gamma [IIa-ATIII] Complex Analysis Per Lane 
  















ATIII] 11.8 33 3.65 6.92 6.21 7.75 2 
 
 








































Table 13: ATIII-M Analysis Per Lane 
  














ATIIIM 2.82 4.47 0.8 0.54 2.04 0.44 0.49 
 
 








































Table 14: ATIII Analysis Per Lane 
  














ATIII 3.73 5.16 2.8 4.12 5.08 3.75 5.93 
 
 








































Table 15 IIa Analysis Per Lane 
  

























































Table 16: Solvent Front Analysis Per Lane 
  

























































Gel 5 & Gel 6 















































Table 17: Overall Protein Analysis Per Lane 
  














Alpha [IIa-ATIII] 1.58 3.54 12.9 8.19 6.17 4.25 15.9 
Beta [IIa-ATIIII] 27.2 2.65 20.4 32.4 26.8 20.2 40.4 
Gamma [IIa-
ATIII] 19.5 27 2.31 9.01 9.74 12.1 5.7 
ATIIIM 1.12 1.23 0.31 2.36 0.81 0.4 2.41 
ATIII 1.3 3.28 1.5 2.9 2.27 2.51 4.06 
IIa 44.9 57.4 23.9 42.2 49.9 57.1 27.9 
Solvent Front 4.42 4.85 38.6 2.93 4.35 3.4 3.63 



































Table 18: Alpha [IIa-ATIII] Complex Analysis Per Lane 
 
  














Alpha [IIa-ATIII] 1.58 3.54 12.9 8.19 6.17 4.25 15.9 
 
 






































Table 19: Beta [IIa-ATIII] Complex Analysis Per Lane 
  














Beta [IIa-ATIIII] 27.2 2.65 20.4 32.4 26.8 20.2 40.4 
 
 







































Table 20: Gamma [IIa-ATIII] Complex Analysis Per Lane 
  















ATIII] 19.5 27 2.31 9.01 9.74 12.1 5.7 
 
 

































































































ATIIIM 1.12 1.23 0.31 2.36 0.81 0.4 2.41 
Table 22: ATIII Analysis Per Lane 
  














ATIII 1.3 3.28 1.5 2.9 2.27 2.51 4.06 
 










































Table 23: IIa Analysis Per Lane 
  














IIa 44.9 57.4 23.9 42.2 49.9 57.1 27.9 
 
 








































Table 24: Solvent Front Analysis Per Lane 
  














Solvent Front 4.42 4.85 38.6 2.93 4.35 3.4 3.63 
 
 








































Table 25: Overall Protein Analysis Per Lane 
 
 







































Alpha [IIa-ATIII] 1.48 2.2 12.1 3.44 4.51 3.62 16 
Beta [IIa-ATIIII] 25.1 2.32 18.9 34.7 23 16.4 39.9 
Gamma [IIa-
ATIII] 18.7 28.7 1.94 9.4 8.65 9.6 8.09 
ATIIIM 0.46 3.03 0.28 2.48 0.53 0.72 1.13 
ATIII 1.63 2.86 1.21 3.29 1.67 1.31 3.58 
IIa 46.9 58.5 22.7 45.4 56.4 64.1 24.7 
Solvent Front 5.8 2.38 42.8 1.26 5.32 4.33 6.61 






     
Error 
 
Table 26: -Alpha [IIa-ATIII] Complex Analysis Per Lane 
  














Alpha [IIa-ATIII] 1.48 2.2 12.1 3.44 4.51 3.62 16 
 
 








































Table 27: Beta [IIa-ATIII] Complex Analysis Per Lane 
  














Beta [IIa-ATIIII] 25.1 2.32 18.9 34.7 23 16.4 39.9 
 
 








































Table 28: Gamma [IIa-ATIII] Complex Analysis Per Lane 
  















ATIII] 18.7 28.7 1.94 9.4 8.65 9.6 8.09 
 
 









































Table 29: ATIII-M Analysis Per Lane 
  














ATIIIM 0.46 3.03 0.28 2.48 0.53 0.72 1.13 
 








































Table 30: ATIII Analysis Per Lane  
  
















































































































IIa 46.9 58.5 22.7 45.4 56.4 64.1 24.7 


























































Solvent Front 5.8 2.38 42.8 1.26 5.32 4.33 6.61 
Tables used for P Value Analysis 
 















ATIII] 13.8 6.4 37.7 34.2 24.7 24.8 51.9 
Alpha [IIa-
ATIII] 13.7 5.88 35.7 32.9 24 23.2 54.1 
Alpha [IIa-
ATIII] 1.58 3.54 12.9 8.19 6.17 4.25 15.9 
Alpha [IIa-
ATIII] 1.48 2.2 12.1 3.44 4.51 3.62 16 
        
 














Beta [IIa-ATIIII] 36.7 21.7 30.3 39.1 36.4 42.1 32.1 
Beta [IIa-ATIIII] 42.1 21 30.6 39.8 39 41.5 30.9 
Beta [IIa-ATIIII] 27.2 2.65 20.4 32.4 26.8 20.2 40.4 
Beta [IIa-ATIIII] 25.1 2.32 18.9 34.7 23 16.4 39.9 
        
 















ATIII] 12.3 34.2 4.24 6.9 9.36 8.27 2.59 
Gamma [IIa-
ATIII] 11.8 33 3.65 6.92 6.21 7.75 2 
Gamma [IIa-
ATIII] 19.5 27 2.31 9.01 9.74 12.1 5.7 
Gamma [IIa-













Alpha Complex P Values 
Alpha [IIa-ATIII] 
     2.45µg IIa & 4.10µg ATIII 1.0µg Heparin 
Mean 7.64 4.505 
Variance 49.77946667 3.908633333 
t Stat 1.206963841 
 P(T<=t) one-tail 0.156966904 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.313933809 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 1.0µg PS 
Mean 7.64 24.6 
Variance 49.77946667 195.9866667 
t Stat -4.869450252 
 P(T<=t) one-tail 0.008273745 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.016547489 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.07µg SPM 
Mean 7.64 19.6825 
Variance 49.77946667 260.4521583 
t Stat -2.626604748 
 P(T<=t) one-tail 0.039276975 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.07855395 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.7µg SPM 
Mean 7.64 14.845 
Variance 49.77946667 121.0009667 
t Stat -3.621376583 
 P(T<=t) one-tail 0.018106151 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.036212302 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.05µg SPD 
Mean 7.64 13.9675 
Variance 49.77946667 134.694225 
t Stat -2.765732641 
 P(T<=t) one-tail 0.034908445 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.069816889 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.5µg SPD 
Mean 7.64 34.475 
Variance 49.77946667 458.3758333 
t Stat -3.735759315 
 P(T<=t) one-tail 0.016720981 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.033441963 































Beta Complex P Values 
Beta [IIa-ATIII] 
     2.45µg IIa & 4.10µg ATIII 1.0µg Heparin 
Mean 32.775 11.9175 
Variance 64.11583333 118.729225 
t Stat 10.0486789 
 P(T<=t) one-tail 0.001049163 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.002098327 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 1.0µg PS 
Mean 32.775 25.05 
Variance 64.11583333 39.27 
t Stat 6.109137707 
 P(T<=t) one-tail 0.004406754 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.008813508 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.07µg SPM 
Mean 32.775 36.5 
Variance 64.11583333 12.56666667 
t Stat -1.492514518 
 P(T<=t) one-tail 0.116194171 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.232388342 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.7µg SPM 
Mean 32.775 31.3 
Variance 64.11583333 58.14666667 
t Stat 2.16547179 
 P(T<=t) one-tail 0.059480749 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.118961498 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.05µg SPD 
Mean 32.775 30.05 
Variance 64.11583333 186.55 
t Stat 0.845978592 
 P(T<=t) one-tail 0.22985184 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.459703681 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.5µg SPD 
Mean 32.775 35.825 
Variance 64.11583333 25.2225 
t Stat -0.471247413 
 P(T<=t) one-tail 0.334807562 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.669615124 































Gamma Complex P Values 
Gamma [IIa-ATIIII] 
     2.45µg IIa & 4.10µg ATIII 1.0µg Heparin 
Mean 15.575 30.725 
Variance 16.71583333 11.7425 
t Stat -4.058561511 
 P(T<=t) one-tail 0.013480582 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.026961164 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 1.0µg PS 
Mean 15.575 3.035 
Variance 16.71583333 1.184966667 
t Stat 4.894387654 
 P(T<=t) one-tail 0.008159173 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.016318346 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.07µg SPM 
Mean 15.575 8.0575 
Variance 16.71583333 1.781091667 
t Stat 5.377275799 
 P(T<=t) one-tail 0.006297419 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.012594838 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.7µg SPM 
Mean 15.575 8.49 
Variance 16.71583333 2.514466667 
t Stat 4.127209753 
 P(T<=t) one-tail 0.012898409 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.025796817 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.05µg SPD 
Mean 15.575 9.43 
Variance 16.71583333 3.775266667 
t Stat 4.861937628 
 P(T<=t) one-tail 0.00830867 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.016617341 
 t Critical two-tail 3.182446305   
      2.45µg IIa & 4.10µg ATIII 0.5µg SPD 
Mean 15.575 4.595 
Variance 16.71583333 8.063366667 
t Stat 11.41923837 
 P(T<=t) one-tail 0.000720556 
 t Critical one-tail 2.353363435 
 P(T<=t) two-tail 0.001441112 














































































IIa Beta complex goes down with Heparin.  IIa Gamma complex goes up when in the presence of 
Heparin, consistently.  IIa Alpha complex stays near a similar value when in the presence of Heparin. 
 
This means that Heparin promotes the overall degradation of IIa-Alpha ATIII to IIa- Gamma ATIII.  
PS: 
There is a noticeable large increase in the Alpha Complex when in the presence of PS.  For Beta there is a 
decrease when in the presence of PS.  The Gamma IIa complex experiences a large decrease when in the 
presence of PS. 
0.07 SPM: 
IIa Alpha shows a large increase in the presence of 0.07SPM.  IIa Beta shows a slight increase.  However, 
IIa-Gamma, shows consistent decrease when in the presence of 0.07SPM.  
0.7 SPM 
IIa Alpha shows a large increase when in the presence of 0.7 SPM.   IIa Beta maintains its complex when 
in the presence of 0.7SPM.  IIA Gamma shows a large decrease when in the presence of 0.7 SPM. 
SPM’s by in large act similarly to PS. 
0.05 SPD 
IIA alpha all show a large increase when in presence of 0.05SPD.  IIa beta maintains complex in 
comparison to control when with 0.05 SPD.  The gamma IIA complex shows a large decrease, 
consistently.  
0.5SPD 
IIA alpha shows a large increase in the presence of 0.5 SPD.  IIa Beta maintains the complex mostly.  IIa 
Gamma shows a large decrease. 
 




Protamine Sulfate appears to promote the creation of the Alpha [IIa-ATIII] Complex while nearly 
eliminating the Beta [IIa-ATIII] Complex.  Heparin does the opposite.  SPM and SPD appear to act more 
similarly to Protamine Sulfate.  No IIa was detected; perhaps it was all used in the complex formation or 
left in the loading dye. 
 
Interpreting the Results 
 
 Overall, it would appear that Spermine and Spermidine act more like Protamine 
Sulfate than Heparin, inhibiting complex formation.  However, Spermine and Spermidine do not 
completely block out the complexes in any experiment but significantly lessen them when 
compared with Heparin.  
  In the IXa experiments,  Protamine Sulfate completely blocked the formation of the 
[IXa- ATIII] band.  Spermine and Spermidine both inhibited the complex but did not completely 
eliminate it.   
 In the Xa experiments, it is harder to determine how Spermine and Spermidine act.  
However, when observing the P Values as well as the photographs and the coorosponding data, 
we can make fairly accurate determinations.  The p-values are the best in the primary alpha 
complex while the primary beta has low but not super desireable values.  The tertiary alpha and 
beta values are higher but this is expected due the the degradation required to move from 
complex to complex in the blood cascading system.   When observing the photographs, we see 
that Heparin has dark primary alpha and beta bands while protamine sulfate has lower bands.  
Spermine and Spermidine have primary alpha and beta bands that are darker than protamine 
sulfate and either equivalent or under that of heparin.  The most noticeably change is the 
behavior in the tertiary complexes.  We see Protamine Sulfate form darker tertiary alpha and 
beta bands than Heparin.  Spermine and Spermidine form tertiary bands but their formation 
appears to resemble that of protamine sulfate.  Human Factor Xa may benefit from more 
experiments but there will see be differences in values because of how quickly complex 
degradation can happen.   
 In the XIa experiment, Spermine and Spermidine appear to completely block the 
[XIa-(ATIII)2] secondary complex while there is a huge decrease in the [XIa-ATIII] complex 
when compared with heparin. Heparin has a small [XIa-(ATIII)2] secondary complex formation 
and a significant [XIa-ATIII] complex while Protamine Sulfate does not appear to form any 
secondary complex. Therefore, we see that Spermine and Spermidine are acting more like 
Protamine Sulfate. 
 In the IIa experiments, we see that Spermine and Spermidine increase the formation 
of the alpha and beta [IIa-ATIII] complexes but there is a significant decrease in the gamma [IIa-
ATIII] complex.  Heparin, however, has small amounts of the alpha and beta complexes and a 
large amount of the gamma.  This is due to Heparin promoting the degeneration from alpha, to 
beta, and then to gamma.  Protamine Sulfate appears to form large alpha and beta complexes and 
a small gamma complex in the experiments.  Therefore, it is seen that Spermine and Spermidine 
act most like Protamine Sulfate when in the presence of IIa.   
 Therefore, we see that Spermine and Spermidine act more like Protamine Sulfate 
and inhibit complex formation.  Since Heparin is defined as a coagulant, based on these 
experiments, it may be acceptable to classify Spermine and Spermidine as anti-coagulants.  
















What I Have Gained 
 
 My learning style enables me to thrive in laboratory environments.  I enjoy getting to 
be hands and learn from what I see and what I do since it is all very concrete.  I actually have not 
taken my biochemistry course yet, that is my senior year science class.  I believe it would be easy 
to say that I will have a slight leg up on my future classmates, at least in the laboratory portion.   
 I have learned how to write proper scientific reports and how to determine if my 
results are accurate. This can be seen in this honors project, my use of p-values and the 
interpretation of such values, as well as my other lab reports.   I have learned what is expected in 
a publication, since it is my intention to have this work published.   I have also learned a lot 
about collaboration.  I have had to collaborate between myself and my mentor (Dr. Brecher), 
those who have assisted me, as well the future publishers since these experiments do have to 
meet their standards.   
 This academic research has allowed me to grow as a student and young adult as well.  
The research, while time consuming, has forced me to maintain adequate time management but 
taught me about where my strengths are and where I can improve.  However, I think the most 
important thing I have gained is enjoyment.  I am not required to do research to graduate and it is 
not required for graduate school.  Yet, I have continued to do so because I am good at it and I 


































Gel 2:  
 
             
             


















































































































































































































Graphs Used to Determine Percent of Complex Formations 
 
 
Lane Graph Examples 
On all graphs, I would use a tool to cut out background noise and separate peaks.  I would also 
double check on the gel to determine where there might be error (black dots, etc.)  These errors 
would also be cut out.  Then, the peak percentage would be calculated. 
 

































Xa Lane Examples 
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